In this issue:
Methotrexate vs biologics for paediatric psoriasis
Dose reduction of biologics in stable psoriasis
BMI and efficacy/safety of brodalumab and ustekinumab in psoriasis
Safety of guselkumab in psoriasis patients with latent tuberculosis
Secukinumab for moderate-tosevere palmoplantar psoriasis
Lebrikizumab for moderate-tosevere atopic dermatitis
High-dose, high-frequency infliximab for hidradenitis suppurativa
Ustekinumab for hidradenitis suppurativa
Immune-related adverse events in nivolumab-treated advanced mucosal melanoma
Panitumumab for unresectable cutaneous squamous-cell carcinoma
Please login below to download this issue (PDF)